Design Therapeutics, Inc. (DSGN) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 3 Buy, 3 Hold.
The consensus price target is $15.67 (low: $14.00, high: $18.00), representing an upside of 24% from the current price $12.64.
Analysts estimate Earnings Per Share (EPS) of $-0.90 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.88 vs est $-0.90 (beat +2.2%). 2025: actual $-1.22 vs est $-1.30 (beat +6.3%). Analyst accuracy: 96%.
DSGN Stock — 12-Month Price Forecast
$15.67
▲ +23.97% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Design Therapeutics, Inc., the average price target is $15.67, with a high forecast of $18.00, and a low forecast of $14.00.
The average price target represents a +23.97% change from the last price of $12.64.
Highest Price Target
$18.00
Average Price Target
$15.67
Lowest Price Target
$14.00
DSGN Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Design Therapeutics, Inc. in the past 3 months
EPS Estimates — DSGN
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.88
vs Est –$0.90
▲ 2.3% off
2025
Actual –$1.22
vs Est –$1.30
▲ 6.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — DSGN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
